Vitamin D in kidney disease: Pathophysiology and the utility of treatment

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 2, 2010, Pages 355-363

  Qazi, Rizwan A ^a   Martin, Kevin J ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Hyperparathyroidism; Hyperphosphatemia; Survival; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; OXYGENASE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHORUS; VITAMIN D; VITAMIN D BINDING PROTEIN;

CALCIUM HOMEOSTASIS; CHRONIC KIDNEY DISEASE; DIALYSIS; FRACTURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; OSTEOLYSIS; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

ANIMALS; CALCIUM; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; DIETARY SUPPLEMENTS; FRACTURES, BONE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; KIDNEY DISEASES; MICE; PHOSPHORUS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77953928706     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.02.005     Document Type: Review

References (52)

1. Moe S., Drueke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006, 69(11):1945-1953.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, 76(113):S1-130.
3. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-201.
4. Blacher J., Guerin A.P., Pannier B., et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38(4):938-942.
5. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342(20):1478-1483.
6. Moe S.M. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006, 36(Suppl 2):51-62.
7. Hilpert J., Wogensen L., Thykjaer T., et al. Expression profiling confirms the role of endocytic receptor megalin in renal vitamin D3 metabolism. Kidney Int 2002, 62(5):1672-1681.
8. Willnow T.E., Nykjaer A. Pathways for kidney-specific uptake of the steroid hormone 25-hydroxyvitamin D3. Curr Opin Lipidol 2002, 13(3):255-260.
9. Nykjaer A., Fyfe J.C., Kozyraki R., et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A 2001, 98(24):13895-13900.
10. Leheste J.R., Rolinski B., Vorum H., et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999, 155(4):1361-1370.
11. Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96(4):507-515.
12. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005, 289(1):F8-28.
13. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998, 338(12):777-783.
14. Gonzalez E.A., Sachdeva A., Oliver D.A., et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004, 24(5):503-510.
15. LaClair R.E., Hellman R.N., Karp S.L., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005, 45(6):1026-1033.
16. Jacob A.I., Sallman A., Santiz Z., et al. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984, 114(7):1313-1319.
17. Perwad F., Azam N., Zhang M.Y., et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005, 146(12):5358-5364.
18. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19(3):429-435.
19. Usatii M., Rousseau L., Demers C., et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int 2007, 72(11):1330-1335.
20. Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71(1):31-38.
21. Patel S.R., Ke H.Q., Vanholder R., et al. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995, 96(1):50-59.
22. Slatopolsky E., Finch J., Denda M., et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996, 97(11):2534-2540.
23. Giachelli C.M., Jono S., Shioi A., et al. Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001, 38(4 Suppl 1):S34-S37.
24. Jono S., McKee M.D., Murry C.E., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000, 87(7):E10-E17.
25. Moe S.M., Chen N.X. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008, 19(2):213-216.
26. Al-Aly Z., Qazi R., Gonzalez E.A., et al. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007, 50(1):59-68.
27. Zisman A.L., Hristova M., Ho L.T., et al. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007, 27(1):36-43.
28. Finch J.L., Brown A.J., Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999, 10(5):980-985.
29. Slatopolsky E., Finch J., Ritter C., et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995, 26(5):852-860.
30. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288(1):E125-E132.
31. Bodyak N., Ayus J.C., Achinger S., et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A 2007, 104(43):16810-16815.
32. Zhou C., Lu F., Cao K., et al. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008, 74(2):170-179.
33. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16(4):1115-1125.
34. Teng M., Wolf M., Lowrie E., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. New Engl J Med 2003, 349(5):446-456.
35. Melamed M.L., Eustace J.A., Plantinga L., et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006, 70(2):351-357.
36. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006, 70(10):1858-1865.
37. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70(4):771-780.
38. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008, 168(4):397-403.
39. Shoben A.B., Rudser K.D., de Boer I.H., et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19(8):1613-1619.
40. Dobnig H., Pilz S., Scharnagl H., et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Inter Med 2008, 168(12):1340-1349.
41. Liu P.T., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311(5768):1770-1773.
42. Gombart A.F., Bhan I., Borregaard N., et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis 2009, 48(4):418-424.
43. Aschenbrenner J.K., Sollinger H.W., Becker B.N., et al. 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001, 100(2):171-175.
44. Kruger S., Kreft B. 1,25-Dihydroxyvitamin D3 differentially regulates IL-1alpha-stimulated IL-8 and MCP-1 mRNA expression and chemokine secretion by human primary proximal tubular epithelial cells. Exp Nephrol 2001, 9(3):223-228.
45. Kuhlmann A., Haas C.S., Gross M.L., et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004, 286(3):F526-F533.
46. Mizobuchi M., Morrissey J., Finch J.L., et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007, 18(6):1796-1806.
47. Schwarz U., Amann K., Orth S.R., et al. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998, 53(6):1696-1705.
48. Subramaniam N., Leong G.M., Cock T.A., et al. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001, 276(19):15741-15746.
49. Zhang Z., Sun L., Wang Y., et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008, 73(2):163-171.
50. Zhu K.J., Shen Q.Y., Zheng M., et al. Effects of calcitriol and its analogues on interaction of MCP-1 and monocyte derived dendritic cells in vitro. Acta Pharmacol Sin 2001, 22(1):62-65.
51. Agarwal R., Acharya M., Tian J., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005, 68(6):2823-2828.
52. Fishbane S., Chittineni H., Packman M., et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009, 54(4):647-652.